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ABSTRACT
The geroncogenesis hypothesis postulates that the decline in metabolic 
cellular health that occurs naturally with aging drives a “field effect” predisposing 
normal tissues for cancer development. We propose that mutations in the cancer 
susceptibility genes BRCA1/2 might trigger “accelerated geroncogenesis” in breast 
and ovarian epithelia. By speeding up the rate at which the metabolic threshold 
becomes “permissive” with survival and expansion of genomically unstable pre-
tumoral epithelial cells, BRCA haploinsufficiency-driven metabolic reprogramming 
would operate as a bona fide oncogenic event enabling malignant transformation 
and tumor formation in BRCA carriers. The metabolic facet of BRCA1 one-hit might 
involve tissue-specific alterations in acetyl-CoA, α-ketoglutarate, NAD+, FAD, or 
S-adenosylmethionine, critical factors for de/methylation or de/acetylation dynamics 
in the nuclear epigenome. This in turn might induce faulty epigenetic reprogramming 
at the “install phase” that directs cell-specific differentiation of breast/ovarian 
epithelial cells, which can ultimately determine the penetrance of BRCA defects during 
developmental windows of susceptibility. This model offers a framework to study 
whether metabolic drugs that prevent or revert metabolic reprogramming induced 
by BRCA haploinsufficiency might displace the “geroncogenic risk” of BRCA carriers 
to the age typical for those without the mutation. The identification of the key nodes 
that directly communicate changes in cellular metabolism to the chromatin in BRCA 
haploinsufficient cells may allow the epigenetic targeting of genomic instability 
using exclusively metabolic means. The validation of accelerated geroncogenesis 
as an inherited “one-hit” metabolic “field effect” might offer new strategies to 
therapeutically revisit the apparently irreversible genetic-hereditary fate of women 
with hereditary breast-ovarian cancer syndrome.
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Hereditary cancer and the “Angelina Jolie effect”: 
how high celebrity profile can have a major 
impact on worldwide biomedicine
The famous American film actress and director 
Angelina Jolie made public in 2013 [1] and 2015 [2] 
that, due to her high risk of developing cancer, she 
had undergone two surgical interventions: a double 
mastectomy (removal of both breasts), and later a bilateral 
salpingo-oophorectomy (removal of both ovaries and both 
Fallopian tubes). Three women in her family had died 
from the disease, including her mother, and DNA tests had 
revealed that Ms. Jolie carried a mutation in BRCA1, one 
of the cancer susceptibility genes linked to the so-called 
hereditary breast-ovarian cancer syndrome (HBOCS). 
Although hereditary tumors in women that, like Angelina 
Jolie, carry germline mutations in the BRCA1 gene 
account for only a small percentage of breast and ovarian 
cancers (between 5% and 10%), the risk of developing 
the disease throughout their lifetime is much higher (up to 
85%) than for women without the mutation. 
The so-called “Angelina Jolie effect” has 
undoubtedly led to better social awareness of familial 
cancer syndromes and has resulted in an increase in the 
number of women inquiring about genetic screening to 
Figure 1: Hits and tumor formation in hereditary and nonhereditary carcinomas. The mechanisms that underline genetic 
predisposition to cancer were originally clarified by Knudson, who hypothesized that germline mutations occur in one allele of a tumor 
suppressor gene followed by somatic inactivation, or loss of function, of the remaining normal allele through mutations, deletions, or 
epigenetic repression (defined as loss of heterozygosity [LOH]) [15] (model 1). The Knudson “two-hit” hypothesis has been largely 
validated in most forms of autosomal hereditable cancer and has been also extended to sporadic forms of cancer, albeit at a greater level 
of complexity [84]. Because in the nonhereditary scenario, the first somatic mutation might be expected to occur at a rate approximately 
equal to that of the second mutation in the hereditary cases, a “one-hit” clone is a precursor to the tumor formation in nonhereditary forms 
of cancer (model 2), whereas all cells are “one-hit” clones in hereditary cancer syndromes. BRCA1-driven HBOC syndrome, however, 
apparently contradicts the original “two-hit” theory conformed by other familial cancer syndromes, in which consecutive deletion of two 
alleles accelerates tumorigenesis. Cancer predisposition upon inactivation of a single BRCA allele relates to the so-called haploinsufficiency 
phenomenon associated with heterozygosity, which results in genomic instability in breast/ovarian epithelial cells. This in turn may promote 
additional genetic changes in BRCA heterozygous cells, including the acquisition of new mutations that will precede and be permissive with 
the loss of BRCA (e.g., p53, ATM and CHK2) (model 3). The requirement of this “extra-hit”, although incongruous from the viewpoint of 
familial tumorigenesis mediated by tumor suppressor genes such as BRCA1 and BRCA2, appears to enable cancer-prone BRCA “one-hit” 
cells to evade the cell death processes that would otherwise occur upon loss of the remaining wild-type allele. Based on these models, 
cancer metabolic reprogramming is not the cause but rather the consequence of the mutations that originally generated malignancy and 
tumor growth (modified from original drawing published by Lindsay et al. [19]). 
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determine whether they are at a higher risk of developing 
breast and ovarian cancer because of mutations in the 
BRCA1 and BRCA2 genes [3-5]. Unfortunately, this 
“Jolie effect” has not translated, and will not in the 
short or mid-term, into significant changes in the few 
therapeutic options available to these women [6-11], 
namely: 1) undergo a very strict medical surveillance; 
2) take chemopreventive therapy based on the selective 
estrogen-receptor modulator (SERM) tamoxifen -effective 
in a small percentage of cases, and with potential 
acute and long-term side effects- to reduce the risk of 
developing the disease; and 3) choose to have preventive 
surgery with removal of healthy breasts and ovaries, like 
Angelina Jolie, which could have a profound impact on 
the quality of life of the affected women. Thus, although 
other potential agents for chemoprevention, including the 
SERM raloxifene, the aromatase inhibitor exemestane, 
the poly (ADP-ribose) polymerase inhibitors veliparib 
and olaparib [12], and the RANK ligand inhibitor 
denosumab [13], might offer novel approaches for cancer 
prevention in BRCA mutation carriers, it is clear that there 
is an urgent need to offer alternative options to women 
inheriting BRCA mutations. These women are at high risk 
of developing breast and ovarian cancer that is generally 
very aggressive and difficult to treat, and which appears at 
a young age, sometimes making maternity an impossible 
goal to achieve. The question is: is it possible to revert, 
or at least modify, the apparently inevitable genetic-
hereditary destiny of women carrying germline mutations 
in BRCA1 and BRCA2?
“Geroncogenesis”: Metabolic changes during 
aging as cancer enhancers
Among the known factors that contribute to cancer 
onset, the most important factor is age [14]. More than 
60% of all cancers appear in people aged 65-70 years. 
Why? In 1971, Dr. Alfred Knudson proposed the “two-
hit” hypothesis to explain the early onset at multiple 
Figure 2: The “geroncogenic” hypothesis of carcinogenesis. The natural deterioration in the function of cellular metabolism 
that occurs with age can be sufficient to generate an aberrant metabolic state in normal tissues capable of facilitating the independent or 
subsequent acquisition of cancer-driving genetic alterations (modified from original drawing published by Lindsay et al. [19]). While the 
model predicts that the geroncogenic risk could increase with excessive calorie intake and/or a sedentary lifestyle, it also suggests the 
possibility of countering this risk with low-calorie diets, physical exercise and by gerosuppressant agents such as metformin, rapamycin, 
and plant-derived polyphenols including resveratrol [85-87]. 
Oncotarget11962www.impactjournals.com/oncotarget
sites in the body of an inherited form of cancer called 
hereditary retinoblastoma [15] (Figure 1, model 1). 
Knudson postulated that inheriting one de novo germline 
copy of a damaged gene present in every cell in the body, 
the so-called “first hit”, was not sufficient to enable 
retinoblastoma and other hereditary cancer syndromes to 
develop. The acquisition of a “second hit” to the remaining 
“healthy” copy in the gene pair was required and could 
occur somatically, which might rapidly lead to cancer 
because both copies of the normal tumor suppressor gene 
would be lost. Nonhereditary forms of the same cancer 
type would be poised to arise when two somatic mutations 
occurred in the same cell in susceptible tissue (Figure 1, 
model 2). Knudson´s hypothesis predicts that the chances 
for a germline mutation carrier to get a second somatic 
mutation at any of the multiple sites in their body are much 
greater than the chances for non-carriers to get two hits 
in the same cell. Thus, although the “first hit” germline 
mutation at the genotypic level is actually inherited 
in an autosomal dominant fashion, tumor suppressors 
apparently act recessively at the phenotypic level, i.e., 
both alleles must be mutated/lost for cancer to develop. 
According to the widely accepted “two-hit” hypothesis 
of Knudson [15], tumors appear more frequently in the 
elderly because cells require time to accumulate enough 
oncogenic mutations to reach the minimum threshold of 
malignancy that is necessary for tumors to develop in a 
specific organ or tissue (Figure 1, right panel). Knudson’s 
hypothesis of carcinogenesis, however, cannot explain 
why cancer risk is significantly reduced by calorie 
restriction or physical exercise, and also why an excess 
of calories and a sedentary lifestyle have the opposite 
effect [16]. Calorie restriction, up to 70% of ab libitum 
consumption, can completely halt tumor formation even 
in situations where chemical carcinogens would normally 
induce tumor formation in 100% of cases [17, 18; Figure 
2]. 
Based on the classic Knudson model, the commonly 
observed metabolic changes in all types of cancer are not 
the cause but rather the consequence of the mutations 
that originally generated the aberrant tumor growth. 
Conversely, it has recently been postulated that tumor 
formation might not only depend on accumulating 
mutations in the genome, in a temporal manner, but also 
on the decline in the homeostasis or “metabolic health” 
that naturally occurs in our cells as we age [19-23]. 
Thus, the natural deterioration of the bioenergetic and 
biosynthetic machinery in normal cells could facilitate the 
genesis of an aberrant metabolic state favorable to support 
the processes of malignant transformation (Figure 2). 
This implies that, as we age, the possibility that genetic 
aberrations take place in a cell “pre-equipped” with a 
metabolism permissive for a process so bioenergetically 
and biosynthetically demanding as tumor transformation 
will increase. In this alternative model of carcinogenesis, 
known as geroncogenesis [19-21], the metabolic health of 
our cells would be a determinant factor to push the risk 
balance or “cancer risk-meter” to one side or the other. 
Thus, while the model predicts that the “geroncogenic” 
risk could increase with excessive calorie intake and 
a sedentary lifestyle, it also suggests the possibility of 
counteracting this risk with low-calorie diets and physical 
exercise. Realistically, the geroncogenic model adequately 
explains not only the observation that the major risk factor 
for cancer is age, but it is also consistent with the known 
associations between cancer prevalence and obesity and/or 
type 2 diabetes [24, 25], and the chemopreventive effect of 
molecules that maintain the metabolic health within cells, 
such as the polyphenol resveratrol [26, 27] or the anti-
diabetic drug metformin [28-31].
The enigmatic process of tumor formation in 
BRCA mutation carriers: still a topic of discussion 
20 years after its discovery
It may seem surprising, but the mechanisms 
underlying tumor formation in women carrying 
heterozygous pathogenic mutations in one of the BRCA 
alleles inherited from one of the progenitors are still 
unknown despite more than 20 years passing since their 
discovery [32-35]. 
In hereditary familial cancer syndromes, 
individuals are termed heterozygous (having one or more 
dissimilar gene pairs) because they begin life with a 
germline mutation in one of the alleles linked to cancer 
susceptibility (e.g., BRCA1/2 alleles in the HBOCS) that 
is balanced by a normal counterpart. According to the 
“two-hit” postulate of Knudson [15], these individuals are 
predisposed to cancer since all of their cells have already 
sustained the first hit to cancer-linked genes (Figure 1, 
model 1). Thus, when the critically needed normal tumor 
suppressor gene that balances this germline mutation is 
lost at some point during the life of a carrier, a condition 
called loss of heterozygosity (LOH) occurs, which 
constitutes the most common molecular genetic alteration 
in human cancers. However, several factors make familial 
BRCA tumors not only extraordinarily complex but also 
enigmatically paradoxical. It is known that the wild-type 
alleles of the BRCA genes are lost in all the ovarian tumors 
and in a significant number of breast tumors that develop 
in women carrying a mutated allele [36]. Paradoxically, 
the complete absence of BRCA genes in adult human 
cells induces significant defects in cell proliferation that 
leads ultimately, in the majority of cases, to cell death. 
Moreover, this bi-allelic inactivation of BRCA observed 
in patient tumors results in early embryonic lethality when 
reproduced in animal models [37-39]. Globally, these 
studies show that: a) BRCA genes are essential for life 
since it is impossible to obtain live animals in the absence 
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of this protein and, b) BRCA genes play an essential role in 
the maintenance of the genomic integrity of normal cells 
[40-42]. This raises the question, how can tumor cells 
survive with loss of both BRCA1 alleles? 
If we consider that BRCA1/2 function as tumor 
suppressors in normal cells [36], BRCA tumor formation 
should presumably follow the “two-hit” theory, which 
would satisfactorily explain the accelerated carcinogenesis 
that occurs in other familial cancer syndromes [15]; that 
is, in those individuals with a genetic predisposition to 
cancer because of an inherited mutated allele in a tumor 
suppressor gene, it is considered that somatic LOH (i.e., 
the loss of the healthy allele) is a compulsory step for 
tumor formation and/or progression in those syndromes. 
However, to survive homozygotic inactivation of the 
BRCA genes during tumorigenesis, pre-tumoral cells in 
carriers must accumulate additional genetic alterations 
in other genome “guardian” genes, such as the tumor 
suppressor p53. Therefore, the requirement for an “extra-
hit” to explain the process of familial tumorigenesis 
mediated by tumor suppressor genes such as BRCA1/2 
seems contradictory (Figure 1, model 3). The genomic 
instability that arises as a consequence of the inactivation 
of just one of the two BRCA alleles (a phenomenon 
known as haploinsufficiency) has been proposed as the 
mechanism that facilitates the acquisition of additional 
genetic alterations [40, 43, 44]. 
If the role of BRCA genes in a normal cell is to 
safeguard its malignant transformation, it would be 
expected that a 50% reduction in the expression of BRCA 
in women mutation carriers would coalesce with the 
emergence of a broad spectrum of tumors in all tissues. 
However, the loss of one half of the protective dosage of 
BRCA1/2 proteins increases the risk of tumor formation 
preferentially in hormone-dependent tissues such as 
mammary and ovarian epithelia. Although the enigma 
of this tissue-specificity for BRCA tumors [45] remains 
unresolved, numerous lines of evidence converge and 
suggest that the process of haploinsufficiency is capable 
of pre-initiating significant changes in the activation 
state of the hormonal signaling cascade (estrogen and 
progesterone receptors) that occurs naturally in those 
epithelial tissues, which in turn would lead to genomic 
instability phenomena and the acquisition of new 
Figure 3: BRCA1 haploinsufficiency induces “accelerated geroncogenesis”. Women carrying mutations in the cancer 
susceptibility genes BRCA1 and BRCA2 might undergo a tissue- and cell type-specific process of “accelerated geroncogenesis” in breast 
and ovarian epithelia. BRCA1 haploinsufficiency-driven metabolic rewiring of breast/ovarian epithelial cells to metabolic portraits capable 
of supporting the high bioenergetic and biosynthetic requirements of genomically unstable breast/ovarian epithelial cells to progress to a 
fully malignant phenotype might constitute an unanticipated and inherited form of metabolic reprogramming linked to increased risk of 
oncogenesis (modified from original drawing published by Lindsay et al. [19]). In this model of “accelerated geroncogenesis”, there would 
be a reduction in the time required for breast and ovarian epithelial cells to phenocopy a cancer-like metabolism, thus accelerating the 
rate at which the metabolic threshold becomes “permissive” with the survival and expansion of the pre-tumoral “one-hit” BRCA-deficient 
breast/ovarian epithelial cells. Although BRCA haploinsufficiency per se would significantly increase the “geroncogenic” risk, it would also 
make these patients more responsive to preventative and therapeutic strategies based on new drugs or approaches aimed to halt the aberrant 
metabolic reprogramming of breast/ovarian epithelial cells. 
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mutations that will be “permissive” with the total loss of 
BRCA1/2 (e.g., p53, ATM and CHK2) [46-48]. 
Do women carrying BRCA1/2 mutations undergo 
accelerated “geroncogenesis”?
 BRCA heterozygosity seems able to alter, in a subtle 
but significant manner, the gene expression profiles, the 
activation status of intracellular signaling cascades (i.e., 
hormone receptors), the differentiation degree, and the 
genomic stability of epithelial cells that, in every other 
way, are apparently completely normal, including their 
morphology within the mammary or ovarian tissue [49-
53]. This suggests that breast and ovarian tumors could 
develop through a “silent” process in which accumulation 
of molecular changes from very early stages is caused 
by the chronic presence of just one “hit”, BRCA1/2 
haploinsufficiency, which would be sufficient to initiate 
tumor formation by “copying” the behavior of a cancer 
cell. In this scenario, it is important to note the following: 
1. Epidemiological studies have demonstrated that 
physical exercise and absence of obesity in the teenage 
years are protective factors significantly associated with a 
later onset of breast cancer in Ashkenazi Jewish women, 
a population highly likely to inherit BRCA mutations 
[54-56]. Thus, while over 60% of women with a familial 
BRCA1 mutation will develop breast cancer before the age 
of 70, “metabolically healthy” lifestyles might be able to 
significantly reduce the likelihood of pre-tumoral BRCA1 
haploinsufficient cells reaching the malignancy threshold. 
2. Recent studies are beginning to reveal an until 
now unsuspected function of BRCA1 in normal tissues, 
which is the regulation of cellular metabolism [57-62]. 
First, BRCA1 regulates fatty acid biosynthesis both in 
adipose tissue and also in tumor cells [57-60]. Second, 
loss of BRCA1 function induces a reprogramming of 
energetic metabolism in breast cancer cells [61]. Third, 
BRCA1 regulates the process of cellular self-cannibalism 
known as autophagy [62], a complex molecular machinery 
that recycles damaged cellular constituents to mitigate the 
effects of metabolic stress. 
Although none of the above-mentioned studies 
were performed in models of BRCA1 haploinsufficiency, 
it seems reasonable to propose that the tumor suppressor 
function of BRCA1 might involve the participation of 
strictly metabolic mechanisms capable of restricting 
the emergence of a metabolic status compatible with 
malignant transformation. It is within this scenario that we 
postulate a slightly different version of the geroncogenic 
hypothesis in which women carrying mutations in BRCA1 
and BRCA2 might undergo a process of “accelerated 
geroncogenesis” in mammary and ovarian epithelia 
(Figure 3). This new hypothetical framework assumes 
that:
a. BRCA1/2 haploinsufficiency is sufficient 
to produce significant and chronic cell-type-specific 
metabolic changes that would allow the earlier onset of 
an aberrant metabolic state compatible and “permissive” 
with the elevated genomic instability present in breast and 
ovarian epithelial cells in women carrying non-functional 
copies of BRCA1/2. 
b. The inheritance of a mutated allele in BRCA1/2 
might significantly reduce the time required for mammary 
and ovarian epithelial cells to become “pre-equipped” with 
an optimal metabolic performance to support a process so 
bioenergetically (Box 1) and biosynthetically demanding 
as tumor formation. 
c. By accelerating the rate at which the metabolic 
threshold is “permissive” with the survival and the 
expansion of the genomically unstable pre-tumoral cells, 
the metabolic facet of BRCA haploinsufficiency would 
operate as a true oncogenic event capable of provoking 
malignant transformation and tumor formation in women 
carrying the mutation. 
d. BRCA1/2 haploinsufficiency would significantly 
increase the “geroncogenic risk” in these women, but 
also should make them responsive to new preventive 
and therapeutic strategies capable of restoring metabolic 
barriers (Box 1) incompatible with the genomic instability 
that occurs at an early stage in the epithelia of these 
women.
e. The characterization of the “metabolic portrait” 
generated by BRCA1/2 haploinsufficiency might 
inherently determine the preventive and therapeutic value 
of new anti-metabolic strategies in women carrying these 
mutations. 
BOX 1. BRCA1 haploinsufficiency increases the 
metabolic potential of normal-like breast epithelial 
cells: A metabolic pre-adaptation suppressible by 
the mitochondrial poison metformin. To provide a 
preliminary proof-of-concept of the inherited metabolic 
facet of germline BRCA mutations in target tissues, we 
took advantage of isogenic pairs of nontumorigenic 
human breast epithelial cells (MCF10A) in which the 
knock-in of 185delAG mutation in a single BRCA1 allele 
leads to genomic instability [63]. Using a commercially 
available real-time assay on live cells (XFp Cell Energy 
Phenotype Test, Seahorse Bioscience) we measured both 
the mitochondrial and glycolytic activity in BRCA1+/+ 
and BRCA1185delAG/+ cells, and compared their baseline 
values with metabolic activity under stressed conditions 
to determine the so-called metabolic potential, i.e., the 
intrinsic cells’ ability to respond to an energy demand. 
When simultaneously measuring the relative utilization of 
the major energy pathways under both basal and stressed 
conditions, we concluded that BRCA1 haploinsufficiency 
was sufficient to notably augment the normal-like breast 
epithelial cells’ ability to meet an energy demand via 
respiration and glycolysis. Importantly, this advantageous 
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metabolic pre-equipment of BRCA1 haploinsufficient cells 
was notably suppressed by pre-treating BRCA1185delAG/+ 
cells with clinically relevant concentrations (1 µmol/L; 
24 h) of the mitochondrial poison metformin. Indeed, 
metformin pre-treatment of BRCA1185delAG/+ cells restored 
the baseline metabolic potential of BRCA1+/+ parental 
cells, whereas the lower metabolic potential of BRCA1+/+ 
parental cells remained unresponsive to the drug.
Because the metabolic potential can be viewed 
as the functional consequence of somatic or inherited 
germline mutations in terms of metabolic adaptations and 
reprogramming events that drive tumor malignancies, 
these findings support the notion that: a.) BRCA1 
haploinsufficiency might accelerate the geroncogenic 
trait that naturally occurs in the breast epithelium by 
enhancing the metabolic potential of epithelial cells; b.) 
new metabolic strategies (e.g., the mitochondrial poison 
metformin) aimed to halt the breast tissue- and epithelial 
cell-specific metabolic reprogramming imposed by BRCA1 
haploinsufficiency might be explored as preventive and 
therapeutic options in BRCA1 carriers.
Accelerated geroncogenesis in BRCA1 carriers: A 
proof-of-concept framework to validate aberrant 
metabolism as a bona fide “cancer trait”
The clinical relevance of alterations at the “one-hit” 
level to carcinogenesis is highlighted by the fact that a very 
high number of patients with a heritable cancer syndrome, 
Box: OCR: Oxygen Consumption Rates, in pMoles O2/min. ECAR: Extracellular Acidification Rate, in mpH/min. ECAR data 
were not artificially altered by changes in pH values, as in fact closely paralleled changes in PPR (normalized Proton Production Rate, in 
nmol H+/min) values (data not shown)
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including those suffering HBOCS, will develop cancer 
[64]. This supports the notion that specific molecular 
features in otherwise phenotypically normal cells in target 
tissues might be directly associated with actual cancer 
development. Indeed, the fact that germline variants in 
BRCA1/2 are inherited in an autosomal dominant manner 
strongly indicate that molecular features gathered at the 
cellular level in those individuals are directly associated 
with cancer initiation, which may provide further insights 
about the development of specific cancers (e.g., breast and 
ovarian carcinomas). Moreover, alterations in normal-like 
cells from target tissues in patients representing different 
forms of heritable cancer such as HBOCS might be able 
to capture not only changes that are unique to a specific 
pathway(s) for HBOCS, but they might also involve 
“global changes” that can be shared, whether systemic or 
at the target site, not only by different forms of heritable 
cancers at the tumor level but also by sporadic forms of 
cancer. Because these global changes can be defined as the 
cancer trait, the metabolic characterization of otherwise 
normal breast epithelial cells from one-hit BRCA carriers 
(which do not include most of the confounding secondary 
effects that take place at the two-hit tumor stage) 
should illuminate the earliest metabolic changes (and, 
consequently, therapeutically valuable metabolic targets) 
that represent “engine drivers” in sporadic forms of 
cancer also, which might enable a better prioritization and 
validation of relevant metabolic biomarkers and optimal 
metabolic targets at the “two-hit” tumor stage. 
We propose that metabolomic analyses of 
phenotypically normal, one-hit BRCA breast/ovarian 
epithelial cells might capture early metabolic changes that 
could serve as risk biomarkers and targets for preventive 
agents relevant to the management not only of HBOCS, 
but also of a much larger group of cases of sporadic breast 
and ovarian cancers. By providing the precise metabolic 
mechanisms for tumor initiation in a tissue-dependent 
manner, breast/ovarian epithelial cells from BRCA1 
carriers can therefore be viewed as fertile models not 
only for understanding the basic metabolic mechanisms 
of oncogenesis, but also as idoneous clinical scenarios 
for how to realize the promise of personalized therapeutic 
approaches to metabolic cancer prevention and therapy in 
a much larger group of sporadic cancers.
Nevertheless, we should acknowledge that 
there is no preventive option capable of successfully 
reverting the genetic-hereditary fate in women that 
carry mutations in cancer-predisposing BRCA1/2 genes 
beyond strict surveillance or preventive mastectomy, 
the extreme alternative chosen by Angelina Jolie. 
Assuming that inherited mutations will irreversibly lead 
to cancer in these women, our model of “accelerated 
geroncogenesis” offers an alternative scenario, testable 
from a therapeutic point-of-view, where energetic 
behaviors or new drugs that prevent or revert the pro-
tumoral metabolic alterations induced at an early stage by 
haploinsufficiency of BRCA1/2, could restore metabolic 
barriers for the processes of genomic instability that 
occur in the epithelia of these women. This would 
displace their “geroncogenic risk” to the age typical for 
women without the mutation. Thus, our model a priori 
predicts that “metabolically healthy” lifestyles (e.g., 
daily physical exercise, intermittent fasting) and, more 
specifically, the use of anti-metabolic drugs to stop or 
revert the metabolic reprogramming induced by BRCA1/2 
haploinsufficiency in the epithelia of target tissues, could 
be new effective strategies for the early prevention and 
therapeutic treatment by displacing the “geroncogenic 
risk” of BRCA carriers. In this regard, it should be noted a 
significant increase in the risk of developing diabetes after 
a breast cancer diagnosis appears to occur in women with 
BRCA1/2 mutation [65]. Because a high Body Mass Index 
(BMI), which is an indicator of high body fatness, and the 
use of chemotherapy, compounded this increased risk in 
BRCA1/2 carriers, further investigation should clarify if, 
in addition to cell-autonomous mechanisms, the metabolic 
facet of BRCA1 one-hit also involves significantly 
imbalanced non-cell-autonomous environmental factors 
(e.g., IGF-I, estrogens) compared to women treated for 
breast cancer who do not have a BRCA mutation [66-68]. 
Accelerated geroncogenesis in BRCA1-
driven HBOCS: Metabolism as the molecular 
bridge connecting irreversible germline 
genetic alterations with reversible epigenetic 
reprogramming
Accumulated evidence indicates that some 
individuals with BRCA1/2 germline variants can survive 
to an elderly age without developing cancer, while 
others never develop cancer. Among those who develop 
cancer, the age of onset and the presentation of the 
disease, also varies. Although no clear explanation exists 
for these observations, it has been generally thought 
that exposure to certain (micro)environmental factors 
ultimately determines the penetrance of tumor suppressor 
gene defects by inducing “second hits” in the normal 
allele or promoting the acquisition of additional genetic 
alterations that are required for multistage carcinogenesis. 
The developmental origins of health and disease 
(DOHaD) hypothesis provides an alternative model 
whereby environmental exposure during development 
increases susceptibility to cancer in adulthood not by 
inducing genetic mutations but by reprogramming the 
epigenome [69]. In the DOHaD framework, BRCA1 
haploinsufficiency-driven altered metabolism during 
development might cooperate to increase the penetrance 
of the defective BRCA1 gene by significantly altering 
the epigenetic machinery in the target cells during 
breast organogenesis, which, in contrast to most organs 
that are fully developed at birth, takes place postnatally 
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in adolescence and in adulthood. One possibility is that 
BRCA1 carriers might develop early aberrant patterns of 
histone and DNA methylation via the ability of BRCA1 
to regulate the abundance of co-factors synthesized in 
mitochondria, which regulate genomic DNA methylation 
and chromatin structure/dynamics within the nuclear 
genome (e.g., acetyl-CoA, α-ketoglutarate, NAD+, FAD, 
or S-adenosylmethionine) (Figure 4). If a breast/ovarian 
epithelial tissue-specific alteration in these metabolic co-
factors, which are associated with processes of active de/
methylation or de/acetylation, occurs because of BRCA1 
haploinsufficiency, faulty epigenetic reprogramming may 
be imparted at the “install phase” that directs cell-specific 
differentiation during the inextricably unidirectional 
program of breast/ovarian development. A metabolically-
driven pre-installation of defective epigenetic programs on 
the genome of these cells might aberrantly pre-adapt the 
developing tissues to the future adult environment, which 
can adversely affect cancer risk during developmental 
windows of susceptibility, thus ultimately determining the 
penetrance of BRCA defects.
Although epigenetic changes might be detected 
in at-risk tissues prior to the development of tumors in 
BRCA1 carriers [67, 68], thus confirming that the effects 
of BRCA deficiency-driven epigenetic reprogramming are 
apparent in the “normal tissue” before the development 
of disease, it remains to be elucidated whether the 
effects of one-hit BRCA1/2 germline mutations on the 
epigenetic landscape of cells at target tissues are a direct 
consequence of altered mitochondrial metabolic status 
and/or changes in one-carbon metabolism [73-74] in 
BRCA1 haploinsufficient breast/ovarian epithelial cells. 
Figure 4: Metabolic regulation of epigenetics: The reprogramming dimension of BRCA1-driven accelerated 
geroncogenesis. Haploinsufficiency for BRCA1/2 can lead to cell-type-specific mitochondrial functioning that invokes a significantly 
altered mitochondria-to-nucleus retrograde response in breast/ovarian epithelia. This response may induce relevant changes to the nuclear 
epigenome via alteration of key metabolic co-factors closely associated with the processes of active de/methylation or de/acetylation (e.g., 
acetyl-CoA, α-ketoglutarate [α-KG], NAD+, FAD, and S-adenosylmethionine [SAM]), which might increase the penetrance of tumor 
susceptibility, but may also illuminate new interventions that can reverse the epigenetic effects of metabolic reprogramming to decrease 
cancer risk associated with germline alterations in BRCA1/2 tumor suppressor genes. 
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Crucially, however, the metabolic nature of this ability to 
reprogram the epigenome intrinsically holds promise for 
new interventions that can target the metabolo-epigenetic 
phenotype [75] of accelerated geroncogenesis. In contrast 
to germline alterations in BRCA1/2 genes, which are 
generally irreversible, the identification of the key nodes 
that directly communicate changes in cellular metabolism 
to the chromatin state in BRCA haploinsufficient breast/
ovarian epithelial cells may revolutionarily allow the 
epigenetic targeting of genomic instability by using 
exclusively metabolic means. Moreover, if the metabolic 
facet of BRCA1 one-hit involves tissue-specific alteration 
of the signaling emanating from mammalian target of 
rapamycin (mTOR), the recently uncovered BRCA1 
haploinsufficiency-induced senescence (HIS) [76] might 
be understood as an accelerated form of mTOR-driven 
“geronconversion” [77-83] specific to epithelial cells. 
Experimental confirmation of the accelerated nature of 
cell- and tissue-specific geroncogenesis in the breast and 
ovarian epithelia of BRCA carriers should provide us with 
unanticipated metabolic tools to therapeutically revisit the 
apparently irreversible genetic-hereditary fate of women at 
high risk of suffering breast and ovarian cancer.
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